Sugi Predict

Sugi Predict / Compounds / SCHEMBL18007685

SCHEMBL18007685

SCHEMBL18007685

CCOC(=O)c1cc(S(=O)(=O)Cl)nn1C

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 1/20 0.49
▸ SMN1; SMN2 Q16637 6/20 0.48
▸ RAB9A P51151 5/20 0.48
▸ NPC1 O15118 3/20 0.48
▸ MAPT P10636 2/20 0.48
▸ KDM4E B2RXH2 3/20 0.46
▸ MEN1 O00255 1/20 0.45
▸ KMT2A Q03164 1/20 0.45
▸ POLB P06746 1/20 0.40
▸ FAAH O00519 2/20 0.39
▸ ATM Q13315 1/20 0.39
▸ TDP1 Q9NUW8 1/20 0.38
▸ NOD2 Q9HC29 1/20 0.38
▸ NOD1 Q9Y239 1/20 0.38
▸ BAZ2B Q9UIF8 1/20 0.38
▸ BAZ2A Q9UIF9 1/20 0.38
▸ ALDH1A1 P00352 1/20 0.37
▸ HPGD P15428 1/20 0.37
▸ HSD17B10 Q99714 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18007604 0.85 LMNA (0.46) LMNASMN1; SMN2RAB9ANPC1MAPT
SCHEMBL19508022 0.83 CA12 (0.39) LMNASMN1; SMN2RAB9ANPC1MAPT
SCHEMBL22680981 0.83 RAB9A (0.50) LMNASMN1; SMN2RAB9ANPC1MAPT
SCHEMBL25033908 0.82 SMN1; SMN2 (0.38) LMNASMN1; SMN2RAB9ANPC1MAPT
SCHEMBL8072052 0.81 LMNA (0.56) LMNASMN1; SMN2RAB9ANPC1MAPT
SCHEMBL19507067 0.79 LMNA (0.52) LMNASMN1; SMN2MAPTKDM4EKMT2A
SCHEMBL1894879 0.78 LMNA (0.52) LMNASMN1; SMN2RAB9ANPC1MAPT
SCHEMBL18029806 0.78 SMN1; SMN2 (0.67) LMNASMN1; SMN2RAB9AMAPTMEN1
SCHEMBL23329033 0.77 MEN1 (0.32) LMNAMAPTKDM4EMEN1KMT2A
SCHEMBL1850876 0.76 LMNA (0.51) LMNASMN1; SMN2RAB9ANPC1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240400502-A1 SULFONYLUREAS AND RELATED COMPOUNDS AND USE OF SAME UNIV QUEENSLAND (AU) 2024-12-05 — — US disclosed
CN-113582889-B Sulfonylureas and related compounds and uses thereof 昆士兰大学 2024-09-20 — — CN disclosed
US-11845715-B2 — — 2023-12-19 — — US disclosed
US-11845715-B2 — — 2023-12-19 — — US disclosed
US-20230382925-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMA (US) 2023-11-30 — — US disclosed
US-20230382924-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS INCORPORATED 2023-11-30 — — US disclosed
US-20230382924-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS INCORPORATED 2023-11-30 — — US disclosed
US-20230382925-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMA (US) 2023-11-30 — — US disclosed
CN-111132974-B Sulfonamide carboxamide compounds 英夫拉索姆有限公司 2023-11-21 — — CN disclosed
CN-116783204-A Modulators of cystic fibrosis transmembrane conductance regulator 弗特克斯药品有限公司 2023-09-19 — — CN disclosed
EP-3578547-A1 SULFONYLUREAS AND RELATED COMPOUNDS AND USE OF SAME The University of Queensland (AU) 2019-12-11 — — EP disclosed
WO-2019034686-A1 NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS INFLAZOME LIMITED (IE) 2019-02-21 — — WO disclosed
WO-2019034690-A1 SULFONYLUREAS AND SULFONYLTHIOUREAS AS NLRP3 INHIBITORS INFLAZOME LIMITED (IE) 2019-02-21 — — WO disclosed
WO-2019034692-A1 SULFONYLUREAS AND SULFONYLTHIOUREAS AS NLRP3 INHIBITORS INFLAZOME LIMITED (IE) 2019-02-21 — — WO disclosed
US-20180044287-A1 SULFONYLUREAS AND RELATED COMPOUNDS AND USE OF SAME INFLAZOME LIMITED (IE) 2018-02-15 — — US disclosed
US-20180044287-A1 SULFONYLUREAS AND RELATED COMPOUNDS AND USE OF SAME INFLAZOME LIMITED (IE) 2018-02-15 — — US disclosed
US-20180044287-A1 SULFONYLUREAS AND RELATED COMPOUNDS AND USE OF SAME INFLAZOME LIMITED (IE) 2018-02-15 — — US disclosed
EP-3259253-A1 SULFONYLUREAS AND RELATED COMPOUNDS AND USE OF SAME The University of Queensland (AU) 2017-12-27 — — EP disclosed
WO-2016131098-A1 SULFONYLUREAS AND RELATED COMPOUNDS AND USE OF SAME THE UNIVERSITY OF QUEENSLAND (AU) 2016-08-25 — — WO disclosed
WO-2016131098-A1 SULFONYLUREAS AND RELATED COMPOUNDS AND USE OF SAME THE UNIVERSITY OF QUEENSLAND (AU) 2016-08-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11845715-B2 — NLRP3, PYCARD, NOD1 LMNA 2579/4885SMN1; SMN2 4023/4885RAB9A 3413/4885
US-20230382925-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR CFTR, SCNN1G, SCNN1B LMNA 3819/4885SMN1; SMN2 4833/4885RAB9A 1655/4885
US-20240400502-A1 SULFONYLUREAS AND RELATED COMPOUNDS AND USE OF SAME NLRP3, PYCARD, IAPP LMNA 2731/4885SMN1; SMN2 3310/4885RAB9A 3614/4885
US-20180044287-A1 SULFONYLUREAS AND RELATED COMPOUNDS AND USE OF SAME NLRP3, PYCARD, IAPP LMNA 2731/4885SMN1; SMN2 3310/4885RAB9A 3614/4885
US-20230382924-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR CFTR, SCNN1G, SCNN1B LMNA 3926/4885SMN1; SMN2 4840/4885RAB9A 1615/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.